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Abstract
Protein degradation through autophagy is  one of  the key pathways that  maintain
proteostasis and neuronal viability. Dysregulation in autophagy has been associated
with a number of major protein aggregation storage disorders that are characterized by
increased cellular vulnerability and susceptibility to undergo cell death. Although the
molecular machinery, the proteome, and the regulation of the autophagy system are
becoming increasingly clear, the specific nature of its dysfunction in the context of
neuronal disease pathogenesis remains largely unclear. Moreover, although the intricate
network of autophagy regulatory proteins with key metabolic checkpoints is increas‐
ingly being revealed, the relationship between autophagy dysfunction, the changing
rate of protein degradation in the specific pathology, and the aggregate prone behavior
of specific candidate proteins remains less understood. Many questions remain and
deserve urgent attention. When does a neuron respond with heightened autophagic
activity and When does the system fail to degrade autophagy cargo? This book chapter
will focus on some of the main challenges in the field of autophagy research, the identity,
and nature of autophagic flux failure in neurodegeneration, current means to discern
and measure autophagic flux dysfunction in neuronal tissue, and recent advances in
compensating  the  flux  offset.  Specifically,  the  role  of  both  macroautophagy  and
chaperone‐mediated  autophagy  in  neuronal  function  and  dysfunction  and  the
spatiotemporal changes in their rates of protein degradation will be discussed and their
molecular interplay highlighted. Finally,  current advances in the use of autophagy
modulators to better control autophagy activity will be stressed and contextualized
within the framework of  re‐establishing neuronal  proteostasis  to favorably control
cellular fate.
Keywords: autophagic flux, proteotoxicity, Alzheimer’s disease, cell death onset, neu‐
rodegeneration, autophagosome, lysosome
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1. Introduction
Maintaining the delicate balance between protein synthesis and the degradation of cytotoxic
aggregate‐prone proteins is crucial for sustained cell growth and development [1]. In neurons,
the continuous removal of deleterious intracellular components, including aberrant protei‐
naceous species and irreversibly damaged organelles, is governed by the machinery of two
proteolytic systems: the ubiquitin proteasome system (UPS) and the autophagy‐lysosome
pathways [2].  While  the activity  of  the UPS is  limited to  the degradation of  short‐lived
cytosolic  and  nuclear  proteins,  the  autophagy  pathways  are  responsible  for  the  bulk
sequestration, degradation, and recycling of long‐lived or misfolded cytosolic proteins and
damaged organelles [3]. Defects in the autophagic pathways are particularly detrimental to
neuronal  cells,  with  heightened  vulnerability  to  the  accumulation  of  toxic  cytoplasmic
components [4, 5]. Autophagy is a highly conserved and tightly regulated pathway that is
constitutively active in all cell types and is markedly induced under stress conditions [6].
Depending on the cargo targeted, and the mode of cargo delivery to the lysosome, autophagy
is  generally  classified into macroautophagy,  chaperone‐mediated autophagy (CMA),  and
microautophagy [7]. All three autophagic pathways usually coexist in the same cell, but only
macroautophagy (henceforth referred to as autophagy) and CMA have been implicated in
the central nervous system and associated with specific neurodegenerative diseases [8]. In
contrast to the distinctive vesicular formation, and the indiscriminate bulk degradation of
cytoplasmic  materials  by  autophagy,  CMA’s  characteristic  feature  is  selectivity,  whereby
cytosolic proteins containing a pentapeptide motif (KFERQ) are targeted and bound by the
cytosolic chaperone heat‐shock cognate protein of 70 kDa (hsc70) and its cochaperones [9].
An estimated 30% of all cytosolic proteins are thought to contain the KFERQ‐like targeting
motif, but this number is likely underrated given that post‐translational modifications can
also render proteins amiable to CMA‐mediated degradation [9]. Similar to autophagy, CMA
is constitutively active in all cell types studied thus far and upregulated in response to various
stressors [10]. Importantly, the inability to upregulate CMA has been shown to render cells
more vulnerable to cell death onset [11]. Neurons are highly efficient in autophagic cargo
degradation [12], which contributes to their heightened vulnerability when autophagic flux,
that is the rate of protein degradation though autophagy, is impaired. Changes in autophagic
flux alter the cell’s susceptibility to undergo cell death and it is becoming increasingly clear
that the autophagic machinery is anchored within an energetic feedback loop that includes
metabolic checkpoints that govern cell survival [13] (Figure 1). It is therefore critical in our
understanding of autophagic flux deviation or dysfunction to reliably and robustly quantify
this process,  in vitro as well  as in vivo.  Autophagic flux is  defined as the rate of  cargo
degradation within autophagosomes through autophagy [4]. Transmission electron micro‐
scopy  (TEM),  Western  blotting,  and  fluorescence  microscopy,  all  of  which  have  been
extensively described elsewhere [14], are widely used in this context. In brief, TEM remains
a most powerful technique for assessing autophagy, as it  allows the identification of the
autophagic machinery structures at nm range [15]. Western blotting monitors endogenous
microtubule‐associated protein 1 light chain 3 (MAP1‐LC3/Atg8/LC3) [16] as well as p62
(sequestosome/SQSTM1) degradation [17] as an indicator of autophagic flux. Importantly, the
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amount of LC3 II correlates with the number of autophagosomes. p62/SQSTM1 is responsible
for selecting cargo and to deliver proteins for degradation. It binds directly to LC3 and is
codegraded by autophagy [18]. Therefore, the total amount of p62 expressed in a given cell
inversely correlates with autophagic flux and provides an indication for the autophagic flux
status. Fluorescence microscopy‐based analysis techniques enable the counting of LC3 and
p62 punctate as well as the quantification of the fluorescence signal at a single‐cell level [19].
However, although above techniques are valuable in assessing whether autophagic flux has
changed, they are most powerful when complemented with single‐cell measurements that
allow the assessment of the organelle pool size of autophagosomes (nA), autophagolysosomes
(nAL), and lysosomes (nL), thus enabling to report on autophagic flux (J) and transition time
(τ).  Currently,  there has been a major progression using such single cell‐based assays to
quantify flux using combinations of live cell imaging and photoswitchable fluorochromes
[19–21]. These techniques are highly aligned with measuring the rate of cargo degradation,
that is degradation per hour, and hence autophagic flux.
Figure 1. Changes in macroautophagy (MA) and chaperone‐mediated autophagy (CMA) impact on cell vulnerability.
The autophagic machinery is anchored within an energetic feedback loop that includes key metabolic checkpoints gov‐
erning proteostasis and cell survival.
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2. Macroautophagy and chaperone‐mediated autophagy in
neurodegeneration: from spatiotemporal changes to complete pathway
failure
A unifying theme in neurodegenerative diseases is the failure of the proteolytic systems to
adequately dispose unwanted, deleterious proteins [22]. The first pathological evidence of
dysfunctional autophagy related to neurodegeneration came from electron microscopy studies
of the Alzheimer’s disease (AD) brain showing amyloid plaque‐associated dystrophic neurites
displaying massive autophagic vacuole (AV) accumulation [23]. Similar observations have
been made in multiple animal models of AD [24] as well as in brains of patients with Parkin‐
son’s disease (PD) [25] and Huntington’s disease (HD) [26]. Although the exact mechanism
underlying autophagic dysfunction in neurodegeneration remains unclear, AV buildup may
result from increased autophagic induction, impairment of downstream degradative processes
in the autophagic pathway, or a decreased rate of autophagosome formation combined with
insufficient lysosomal fusion [27]. The role of chaperone‐mediated autophagy (CMA) in
neurodegeneration is twofold: On the one hand, CMA contributes to the removal of pathogenic
proteins, but, on the other hand, CMA itself becomes functionally affected by the toxicity of
abnormal proteins [28] (Figure 1). In the following section, we will focus specifically on the
three candidate pathologies with emphasis on the variability of autophagy and CMA dys‐
function.
2.1. Alzheimer’s disease
Evidence indicates that abnormal autophagy at the level of induction or autophagosome
formation may contribute to AD pathogenesis as the expression of Beclin 1, an essential
initiator of autophagy, was found to be decreased in AD patients [29, 30], possibly due to an
increase in caspase 3‐mediated cleavage of Beclin 1 [31]. However, a genome‐wide study
reported an upregulation of autophagy in AD due to transcriptional upregulation of positive
regulators of autophagy as well as reactive oxygen species (ROS)‐dependent activation of type
III PI3 kinase, a critical kinase for the initiation of autophagy [32]. Furthermore, accumulation
of electron‐dense autolysosomes in the AD brain indicates lysosomal proteolytic failure [23,
33]. The morphology of such accumulated AVs resembles those resulting from selectively
blocking lysosomal proteolysis through deletion of specific cathepsins or addition of lysosomal
inhibitors [34, 35]. The most common cause of early‐onset, familial AD is autosomal‐dominant
mutation in presenilin 1 (PS1) and PS2 [36], which enhance the disproportionate release of
aggregation prone Aβ. However, not all AD‐linked PS mutations manifest with this effect.
Apart from its role in the cleavage of γ‐secretase, PS1 was suggested to function in calcium
homeostasis [37]. Calcium flux regulates both autophagic induction and lysosomal fusion, and
PS mutations appear to aggravate this dysfunction [24] and may represent a mechanistic link
unifying these pathologies [38]. Therefore, presenilins may affect autophagic flux by facilitat‐
ing two crucial aspects, firstly, vesicle fusion and secondly, lysosomal function [39]. In fact, PS1
is involved in lysosomal acidification and autophagosome‐lysosome fusion, and recent
findings demonstrated its association with defective proteolysis of autophagic substrates in
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AD patients [39, 40]. It was suggested that familial AD‐linked PS1 mutations may have a loss‐
of‐function effect on lysosomal proteolysis that leads to AV accumulation and impaired
autophagic substrate turnover in AD [41]. Moreover, defective axonal transport of AVs is being
implicated in AD pathogenesis. Under normal conditions, immature AVs are transported
retrogradely toward the soma for degradation, but in the AD brain, a significant buildup of
AVs is found within dystrophic neurites, an event that could be mimicked by inhibiting
autophagosome delivery to lysosomes in healthy cells [34]. The exact molecular defects
underlying axonal transport failure remain, however, largely unclear. Neuronal damage may
be further inferred via inflammatory reactions generated by brain amyloid deposits. Such
reactions may affect both neuronal and glial functions [42], with glial autophagy specifically
affecting amyloid processing during the advanced stages of the disease [43].
Moreover, pathogenic variants of proteins, such as mutant tau associated with AD and other
proteinopathies, block CMA leading to increased levels of neurofibrillary tangles [44]. When
mutant tau binds to the lysosomal surface protein LAMP‐2A, it is only partially internalized
and the portion that gains entry is trimmed resulting in smaller amyloidogenic tau fragments
at the lysosomal membrane [44]. Tau fragment oligomerization disrupts lysosomal membrane
integrity and blocks CMA function. In addition, tau oligomers released from the lysosomes
upon membrane rupture may act as a nucleating agent to further seed tau aggregation. It was
suggested that alterations in mTOR signaling and autophagy occur at early stages of the
disease [45]. A significant increase in Aβ (1–42) levels associated with a reduction in autophagy
(Beclin 1 and LC3) was observed in postmortem tissue from the inferior parietal lobule of AD,
amnestic mild cognitive impairment (MCI), and preclinical AD (PCAD) subjects. Hyperacti‐
vation of the PI3K/Akt/mTOR was evident in MCI and AD subjects, but not in PCAD subjects,
indicating that autophagy is dynamically altered early on in the disease pathogenesis of AD.
2.2. Parkinson’s disease
Faulty CMA has been widely reported in both familial [28] and sporadic PD [46]. An important
role for CMA in familial PD was indicated by sequence analysis showing the presence of CMA‐
targeting motifs in the majority of PD‐related proteins. The two most predominantly mutated
proteins affected in PD, α‐synuclein, and leucine‐rich repeat kinase 2 (LRRK2) have been
shown to undergo lysosomal degradation through CMA [28]. Mutant variants of these proteins
fail to reach the lysosomal lumen despite recognition by cytosolic hsc70 and successful delivery
to the lysosomal membrane [28, 47]. Aberrant interactions of these toxic proteins with
lysosomal surface protein LAMP‐2A obstruct internalization [28]. Importantly, such toxic
interactions not only impede the degradation of these proteins but also obstruct the degrada‐
tion of other CMA substrates [28, 47]. In sporadic PD, post‐translational modifications caused
by environmental or cellular stressors may reduce dopamine‐modified α‐synuclein suscepti‐
bility to CMA degradation in a manner similar to mutant α‐synuclein [46]. Moreover, the
persistent binding of modified forms of α‐synuclein to the lysosomal membrane promotes the
formation of highly toxic α‐synuclein oligomers or protofibrils. Studies show that an increase
in the cellular levels of either α‐synuclein [28] or LRRK2 [47] beyond a tolerable threshold has
similar inhibitory effects on CMA activity even in the absence of modifications. Aberrant α‐
Autophagic Flux Failure in Neurodegeneration: Identifying the Defect and Compensating Flux Offset
http://dx.doi.org/10.5772/64197
161
synuclein not only inhibits CMA but also inhibits autophagy [48], while the overexpression of
α‐synuclein blocks autophagosome formation [49]. The block in autophagy through α‐
synuclein overexpression presents early, prior to autophagosome formation, suggesting an
effect on Atg9, the only transmembrane autophagic protein.
Several genes related to PD participate in the removal of damaged mitochondria via the
specialized form of autophagy, termed mitophagy [49]. In nearly 50% of autosomal recessive
PD, and about 15% of sporadic early‐onset PD cases, the PARK2 gene is mutated. The gene
product of PARK2, PARKIN, is a ubiquitin E3 ligase containing a ubiquitin‐like domain, two
RING finger domains, and a conserved region between the RING domains [50]. PARKIN, a
cytosolic protein, plays an important role in eliminating dysfunctional mitochondria [51]. It is
recruited to the membrane of damaged mitochondria and promotes their autophagic degra‐
dation [52]. Degradation of mitochondria is both dependent on the expression of PARKIN and
the presence of Atgs. Another PD‐related protein, PTEN‐induced kinase 1 (PINK1), interacts
with PARKIN. p62 connects ubiquitinated proteins to LC3 for degradation via the autophagic
pathway [18] and the loss of mitochondrial membrane potential promotes p62 accumulation
on clustered mitochondria in a PARKIN‐dependent fashion. It remains, however, less clear
whether p62 is required for mitophagy [53, 54].
2.3. Huntington’s disease
Wild‐type Huntingtin protein (Htt) is a short‐lived, regulatory protein usually degraded
through the ubiquitin proteasome system (UPS) [55]. In HD, the long polyQ may affect the
UPS by obstructing the system with mutant Htt (mHtt) [55, 56]; however, the exact afflic‐
tion remains less clear. In HD, a unique situation arises compared to other neurodegenera‐
tive proteinopathies: Apart from autophagy being dysfunctional, wild‐type Huntingtin
protein (Htt) plays multiple roles in regulating the dynamics of the autophagic process
[57]. mHtt contributes toward the induction of autophagy through mTOR sequestering and
inactivation [58]. Importantly, the autophagosomes detected, while increased in abundance,
appear devoid of contents indicating cargo recognition failure [59]. Hence, a situation aris‐
es where aggregated proteins and damaged organelles are not readily degraded despite the
increase in autophagic induction. The presence of mHtt results in defective autophagy,
leading to increased accumulation of protein aggregates, which in turn leads to compensa‐
tory upregulation of autophagy, resulting in accumulation of mHtt and subsequent toxicity
[57]. mHtt affects autophagosome motility and prevents their fusion with lysosomes, fur‐
ther contributing to the heightened autophagosome pool size [60]. However, the exact
point in disease pathogenesis during which the specific molecular defects manifests re‐
mains elusive. Fusion dynamics may be affected early on in the disease leading to compen‐
sation through alternative pathways followed by autophagic failure to recognize mHtt and
subsequent toxicity, or vice versa [57]. In order to implement a successful autophagic thera‐
peutic strategy in neurodegeneration, such defects need to be precisely mapped and quan‐
tified, in order to correct and offset a specific flux deviation.
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3. Spatiotemporal changes of MA and CMA flux in the pathogenesis of
neurodegeneration
Functional autophagic flux involves both the execution of autophagosome formation and
lysosomal clearance, and dual evaluation is required when studying disease pathology [38].
The presence of autophagosomes alone is not a measure of functional autophagy and auto‐
phagic flux; the net rate of autophagosome content degradation [19, 61] reflects the efficiency
of the process. Many neurodegenerative diseases have been characterized by a low autophagic
flux leading to accumulation of diseased proteins and neurotoxicity [62]. Reports on autopha‐
gic flux are often contradictory as dysfunction in multiple steps of the pathway may be
implicated. In the case of HD, for example, human and rodent samples have been reported to
display increased numbers of autophagosomes while, at the same time, maintaining basal, or
even increased, levels of autophagic flux compared to wild‐type controls [59, 63]. In AD,
decreased expression of autophagic induction proteins and increased activity of autophagy‐
suppressing molecules indicate impaired autophagic induction [30, 64]. However, accumu‐
lating intermediate AVs containing partially digested cargo indicates intact autophagic
induction and failure instead of substrate clearance [23, 30]. Given the number of pathological
events occurring in the lysosomal network of AD neurons, such changes in autophagic status
are likely to reflect different stages of AD progression. During normal ageing, autophagy is
downregulated; however, transcriptional regulation thereof seems to be upregulated in AD
brains [32, 65]. This upregulation may represent a compensatory attempt to increase flux
affected by the defective autophagosome maturation that occurs in AD neurons [38]. Impaired
autophagy was suggested to occur early in the onset of AD and the dysregulated overcom‐
pensation in the advanced stages instead. It becomes clear that a fine dissection and quantifi‐
cation of autophagic flux [19] are required to better elucidate the extent of pathway failure and
to better align autophagy modulating drugs to compensate for the existing offset.
4. Autophagy biomarkers?
There is currently an urgent need for validated biomarkers to guide clinical diagnosis in the
early stages of neurodegenerative disease progression, to estimate disease risk, to evaluate
disease stages, and to monitor progression and/or response to therapy before the brain is
irreversibly damaged [66]. Some of the earliest pathogenic events in AD have also been linked
to the Aβ clearance systems, which consists of an interconnected vesicular network of endo‐
somes, lysosomes, and autophagosomes [67]. These alterations are followed by an increase in
lysosomal biogenesis, autophagy impairment, and loss of function in genes and proteins
related to the lysosomal system in AD [23]. A recent study investigated whether alterations in
the lysosomal system are mirrored in the CSF of AD patients and found that the lysosomal
proteins LAMP‐1 and LAMP‐2 were significantly upregulated in the CSF of AD patients [68].
Moreover, strongly reduced BECN1 levels have been observed in the affected brain regions of
presymptomatic AD patients compared with controls [69]. APP‐transgenic mice with a
homozygous BECN1 deletion (BECN1‐/‐) died during embryogenesis [70], whereas mice
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containing a heterozygous deletion, that is BECN1+/‐, revealed increased Aβ plaque deposition,
neuronal loss, and prominent accumulation of dysfunctional lysosomes containing electron‐
dense material [30].
These data indicate that the autophagy profile changes substantially in the disease pathogen‐
esis, increasing the complexity of treating neuronal autophagy dysfunction. Brain imaging
studies of AD disease progression have previously been monitored by the presence of tangle‐
bearing neurons in selective brain areas classified into Braak stages 0–VI [71, 72]. In Braak
stages V and VI, the clinical diagnosis of dementia is made as NFC‐associated neuropathology
is spread throughout most parts of the neocortex [71, 72]. However, few studies have investi‐
gated the alterations in gene expression patterns throughout the entire course of AD progres‐
sion. These and above data strongly highlight that an assessment of the autophagy proteome,
autophagic as well as CMA flux parameters, and a correlation with clinical data or Braak stages
would be highly beneficial in advancing successful implementation of autophagy modulation
in the clinical scenario.
5. MA and CMA in disease‐specific target protein clearance
Although knowledge of how autophagy and CMA are linked is limited, these two pathways
have been shown to provide an integrated cytoprotective response against various proteotoxic
challenges [11]. Indeed, experimental inhibition of either pathway has been shown to result in
compensatory upregulation of the other, revealing a close “cross talk” between these systems
[11, 73] (Figure 2). For example, blockage of CMA through Lamp‐2A silencing in cultured cells
not only leads to the constitutive upregulation of autophagy [11, 73] but also sensitizes cells
to various stressors, such as oxidative stress [11, 74]. The autophagy–CMA compensatory
response appears to be sequential rather than simultaneous, further stressing the need for a
time‐dependent flux profile assessment in the disease pathogenesis. For example, autophagy
is rapidly upregulated as a transitory response to starvation [75], while CMA is sequentially
upregulated in response to long‐term starvation following the downregulation of autophagy
[76]. In some instances, autophagy and CMA have been shown to degrade the same substrate
proteins, but to varying degree. For example, wild‐type α‐synuclein [28], mutant HTT [77],
and mutant tau protein [44] are all degraded by autophagy and CMA (Figure 2). Therefore, it
is possible that the compensatory upregulation of these pathways may attenuate a specific
disease pathogenesis by preferentially targeting and eliminating a specific candidate mutant
protein aggregate. Indeed, autophagy has been shown to serve as the primary route for mutant
HTT degradation [58, 78] and to eliminate both soluble and mutant tau protein aggregates in
vitro and in vivo models [79, 80]. It would therefore be expected that, in the presence of CMA
dysfunction, autophagy would be upregulated, thereby enabling CMA‐defective cells to
maintain their normal protein degradative capacity to sustain cell viability. However, in
cortical neurons and differentiated SHSY5Y cells, CMA blockage due to the overexpression of
mutant α‐synuclein was not found to result in the compensatory upregulation of autophagic
activity [81]. Instead, it led to the accumulation of autophagosomes, cytoplasmic release of
vacuolar hydrolases, and eventually induced autophagic cell death of primary cortical
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neurons [82, 83]. In this regard, the interaction between autophagy and CMA may be a
detrimental, calling for the need to accurately determine how these pathways are sequentially
activated and why the molecular interplay does not always operate functionally.
6. Flux modulation and future outlook
Autophagy can be modulated through mammalian target of rapamycin (mTOR)‐dependent
and mammalian target of rapamycin (mTOR)‐independent pathways using either pharmaco‐
logical agents or lifestyle interventions. Autophagy upregulation has been shown to clear
various types of aggregate prone proteins in vitro [84–86] as well as in vivo [58, 87, 88].Agents
such as rapamycin, rilmenidine, lithium, and trehalose have been used in various disease
models of AD, PD, and HD and have been shown to reduce the disease pathology (Table 1).
However, the application of these drugs in different cell types, at different concentrations, or
Figure 2. Substantial cross talk exists between macroautophagy (MA) and chaperone mediated autophagy (CMA),
with precision defect localization. This calls for the need to precisely map and quantify both MA and CMA fluxes, in
order to correct and offset the pathological flux deviation, re‐establishing proteostasis.
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varying time durations makes conclusive flux modulation challenging. In addition, autophagic
flux was not always assessed, as the techniques and the approach to accurately measure
autophagy activity have often evolved in parallel. For example, rapamycin has been used to
induce autophagy and has been shown to protect against AD and HD when administered in
COS‐7 cells for 15 and 48 h [84, 86] and in PD models when given at 2 µg/ml in PC12 cells for
48 h [85] (Table 1). The same can be reported in in vivo studies where rapamycin has been used
at different concentration and durations, for example 2.24or 14 mg/kg for 13 weeks or 16 
months, respectively [89, 90]. Rilmenidine has been shown to reduce aggregate prone proteins
associated with HD when administered at 1 µM incortical neurons and PC12 for 8 and 24 h,
respectively [87]. Lithium has been shown to increase the clearance of mutant Huntingtin and
α‐synuclein when given at 10 nM [91] and 15 mM [92] in Hela cells (Table 1).
Intervention Pathology Pathology
specificity 
Model
system 
Concentration
applied 
Duration
applied 
Mode of flux
assessment 
References 
Rapamycin AD Autophagy
induction and
autophagosome
clearance 
COS7 0.2 µg/ml 48 h — Berger et al.
[86]
HD Cargo
recognition 
CO7 0.2 µg/ml 15 h — Ravikumar
et al. [84]
PD Cargo recognition
and autophagy
induction   
PC12 0.2 µg/ml 48 h — Webb et al.
[85]
AD Autophagy
induction and
autophagosome
clearance
Mouse 2.24 mg/kg 1X per
day
WB (LC3II,
p62), FM (LC3
II)
Spilman et al.
[89]
Rilmenidine HD 1 µM 8 and 24 h FM & WB (LC3
II)
Rose et al. [87]
Lithium HD Hela 15 mM 48 h/5
days
FM (LC3) WB
(p62)0
Wu et al. [92]
The application of these drugs in different cell types, at different concentrations or varying durations applied, makes
conclusive flux modulation challenging and calls for enhanced method standardization.
EM, electron microscopy; FM, fluorescence microscopy; and WB, Western blotting.
Table 1. Autophagic flux modulators in key model systems of neurodegenerative disease.
Although it becomes clear that major promise exists to achieve favorable therapeutic effects
through autophagy upregulation, it remains largely unclear what the concentration or dose
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and the duration of exposure should be. In addition, AD, PD, and HD affect the autophagic
pathway in different compartments and subtypes of autophagy, changing autophagic flux
distinctively. Increased autophagic induction prior to developing AD‐like pathology in 3xTg‐
AD mice reduces levels of soluble Aβ and tau, but induction after formation of mature plaques
and tangles has no effect on either pathology or cognition [90]. In a scenario where the
lysosomal clearance of autophagosomes is halted, activation of autophagy will result in an
increase in the harmful accumulation of intermediate AVs [93]. In the case of Aβ, it was found
that autophagosomes in AD brains may be a major reservoir of Aβ [94]; therefore, enhancement
of new autophagosome formation without the parallel increase in their degradation may lead
to an increase in Aβ production and subsequent toxicity [95]. Ideally, modification of auto‐
phagic failure should improve autophagosome clearance via the lysosome. Thus, restoring
normal lysosomal proteolysis may hold a key to optimal therapeutic interventions against AD
[33]. Currently, such therapeutic compounds are not yet available. With regard to the role of
Htt in regulating autophagy, it is necessary to identify therapeutic targets that are able to both
restore Htt function and normalize defects associated with key autophagic processes [57]. CMA
regulation also represents a potential therapeutic target given the cross talk that exists between
autophagic pathways [96]. Currently, it is, however, unclear to what extent autophagic flux is
being affected. This demands a better quantitative assessment of autophagic flux as well as
subsequent improved alignment of autophagy modulators, to allow for precision in compen‐
sating flux offset. Taken together, upregulation of autophagy may be beneficial, especially in
the early stages of disease pathogenesis; however, the precise molecular target within the
autophagy machinery as well as the approach and timing of the intervention has to be strongly
aligned with the particular disease specific autophagic flux deviation. Future studies will
undoubtedly better address these challenges, thereby impacting on the therapeutic success
brought about by autophagic flux control.
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